Molecular Fluorescence Endoscopy Targeting Vascular Endothelial Growth Factor A for Improved Colorectal Polyp Detection

Small and flat adenomas are known to carry a high miss-rate during standard white-light endoscopy. Increased detection rate may be achieved by molecular fluorescence endoscopy with targeted near-infrared (NIR) fluorescent tracers. The aim of this study was to validate vascular endothelial growth factor A (VEGF-A) and epidermal growth factor receptor (EGFR)–targeted fluorescent tracers during ex vivo colonoscopy with an NIR endoscopy platform. Methods: VEGF-A and EGFR expression was determined by immunohistochemistry on a large subset of human colorectal tissue samples—48 sessile serrated adenomas/polyps, 70 sporadic high-grade dysplastic adenomas, and 19 hyperplastic polyps—and tissue derived from patients with Lynch syndrome—78 low-grade dysplastic adenomas, 57 high-grade dysplastic adenomas, and 31 colon cancer samples. To perform an ex vivo colonoscopy procedure, 14 mice with small intraperitoneal EGFR-positive HCT116luc tumors received intravenous bevacizumab-800CW (anti-VEGF-A), cetuximab-800CW (anti-EGFR), control tracer IgG-800CW, or sodium chloride. Three days later, 8 resected HCT116luc tumors (2–5 mm) were stitched into 1 freshly resected human colon specimen and followed by an ex vivo molecular fluorescence colonoscopy procedure. Results: Immunohistochemistry showed high VEGF-A expression in 79%–96% and high EGFR expression in 51%–69% of the colorectal lesions. Both targets were significantly overexpressed in the colorectal lesions, compared with the adjacent normal colon crypts. During ex vivo molecular fluorescence endoscopy, all tumors could clearly be delineated for both bevacizumab-800CW and cetuximab-800CW tracers. Specific tumor uptake was confirmed with fluorescent microscopy showing, respectively, stromal and cell membrane fluorescence. Conclusion: VEGF-A is a promising target for molecular fluorescence endoscopy because it showed a high protein expression, especially in sessile serrated adenomas/polyps and Lynch syndrome. We demonstrated the feasibility to visualize small tumors in real time during colonoscopy using a NIR fluorescence endoscopy platform, providing the endoscopist a wide-field red-flag technique for adenoma detection. Clinical studies are currently being performed in order to provide in-human evaluation of our approach.

[1]  H. Hollema,et al.  Proximal adenomas in hereditary non-polyposis colorectal cancer are prone to rapid malignant transformation , 2002, Gut.

[2]  H. Hollema,et al.  In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft , 2007, Journal of Nuclear Medicine.

[3]  Siavash Yazdanfar,et al.  Detection of colorectal polyps in humans using an intravenously administered fluorescent peptide targeted against c-Met , 2015, Nature Medicine.

[4]  P. Low,et al.  Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results , 2011, Nature Medicine.

[5]  Thomas D. Wang,et al.  Targeted Imaging of Esophageal Neoplasia with a Fluorescently Labeled Peptide: First-in-Human Results , 2013, Science Translational Medicine.

[6]  Helmut Neumann,et al.  Confocal laser endomicroscopy: technical advances and clinical applications. , 2010, Gastroenterology.

[7]  Vasilis Ntziachristos,et al.  Towards clinically translatable NIR fluorescence molecular guidance for colonoscopy. , 2013, Biomedical optics express.

[8]  Melissa L. Korb,et al.  IND-Directed Safety and Biodistribution Study of Intravenously Injected Cetuximab-IRDye800 in Cynomolgus Macaques , 2015, Molecular Imaging and Biology.

[9]  E. D. de Vries,et al.  Toward molecular imaging-driven drug development in oncology. , 2011, Cancer discovery.

[10]  H. Hollema,et al.  89Zr-Bevacizumab PET Visualizes Heterogeneous Tracer Accumulation in Tumor Lesions of Renal Cell Carcinoma Patients and Differential Effects of Antiangiogenic Treatment , 2015, The Journal of Nuclear Medicine.

[11]  A. Bansal,et al.  Correlation of Epidermal Growth Factor Receptor With Morphological Features of Colorectal Advanced Adenomas: A Pilot Correlative Case Series , 2010, The American journal of the medical sciences.

[12]  Eva M. Sevick-Muraca,et al.  Single-Dose Intravenous Toxicity Study of IRDye 800CW in Sprague-Dawley Rats , 2010, Molecular Imaging and Biology.

[13]  Esa Läärä,et al.  Development of colorectal tumors in colonoscopic surveillance in Lynch syndrome. , 2007, Gastroenterology.

[14]  E. Kuipers,et al.  A back-to-back comparison of white light video endoscopy with autofluorescence endoscopy for adenoma detection in high-risk subjects , 2010, Gut.

[15]  Muhammad F Dawwas,et al.  Adenoma detection rate and risk of colorectal cancer and death. , 2014, The New England journal of medicine.

[16]  Michael Vieth,et al.  In vivo molecular imaging of colorectal cancer with confocal endomicroscopy by targeting epidermal growth factor receptor. , 2010, Gastroenterology.

[17]  Ying Feng,et al.  In Vivo Fluorescence-Based Endoscopic Detection of Colon Dysplasia in the Mouse Using a Novel Peptide Probe , 2011, PloS one.

[18]  N. Marcon,et al.  Missed Adenomas during Colonoscopic Surveillance in Individuals with Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) , 2008, Cancer Prevention Research.

[19]  G. V. van Dongen,et al.  Inert coupling of IRDye800CW to monoclonal antibodies for clinical optical imaging of tumor targets , 2011, EJNMMI research.

[20]  Rebecca C Fitzgerald,et al.  Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus , 2012, Nature Medicine.

[21]  E. Paulson,et al.  Analysis of air contrast barium enema, computed tomographic colonography, and colonoscopy: prospective comparison , 2005, The Lancet.

[22]  M. Watson,et al.  Correlating EGFR Expression with Receptor-Binding Properties and Internalization of 64Cu-DOTA-Cetuximab in 5 Cervical Cancer Cell Lines , 2008, Journal of Nuclear Medicine.

[23]  Thomas D. Wang,et al.  Multispectral endoscopic imaging of colorectal dysplasia in vivo. , 2012, Gastroenterology.

[24]  Stephen B Fox,et al.  The angiogenic switch for vascular endothelial growth factor (VEGF)‐A, VEGF‐B, VEGF‐C, and VEGF‐D in the adenoma–carcinoma sequence during colorectal cancer progression , 2003, The Journal of pathology.

[25]  Vasilis Ntziachristos,et al.  Real-time intraoperative fluorescence imaging system using light-absorption correction. , 2009, Journal of biomedical optics.

[26]  Martin Goetz,et al.  Molecular imaging in endoscopy , 2013, United European gastroenterology journal.

[27]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[28]  Jeongmin Choi,et al.  Comparison of detection and miss rates of narrow band imaging, flexible spectral imaging chromoendoscopy and white light at screening colonoscopy: a randomised controlled back-to-back study , 2013, Gut.

[29]  D. Heresbach,et al.  Miss rate for colorectal neoplastic polyps: a prospective multicenter study of back-to-back video colonoscopies , 2008, Endoscopy.

[30]  N. Suzuki,et al.  Narrow band imaging for colonoscopic surveillance in hereditary non-polyposis colorectal cancer , 2007, Gut.

[31]  S. Cross,et al.  The angiogenic switch occurs at the adenoma stage of the adenoma–carcinoma sequence in colorectal cancer , 2007, Gut.

[32]  Vasilis Ntziachristos,et al.  Intraoperative Near-Infrared Fluorescence Tumor Imaging with Vascular Endothelial Growth Factor and Human Epidermal Growth Factor Receptor 2 Targeting Antibodies , 2011, The Journal of Nuclear Medicine.